<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2014-02-11 13:33:19Immunology Autoimmune diseases Biology Treatment of multiple sclerosis Genzyme Alemtuzumab Interferon beta-1a Sanofi Interferon Multiple sclerosis Cytokines Immune system |
 | United States Court of Appeals For the First Circuit NoANITA HOCHENDONER ET AL., Plaintiffs, Appellants, v.DocID: 1rtqA - View Document |
 | PRESS RELEASE For Canadian media only Sanofi to Return Allerject® (epinephrine injection, USP) Rights to kaléo Laval, Qc. - February 23, Sanofi (EURONEXT : SAN and NYSE : SNY) announced todayDocID: 1rewx - View Document |
 | genzyme_anzeige_290x60_2014-02-07_D_v02_em.inddDocID: 1pkK1 - View Document |
 | United States Court of Appeals for the Federal Circuit ______________________ GENZYME THERAPEUTIC PRODUCTS LIMITED PARTNERSHIP,DocID: 1oYEH - View Document |
 | IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GENZYME CORPORATION and SANOFI-AVENTIS U.S. LLC, Plaintiffs/Counterclaim-Defendants, Plaintiffs,DocID: 1omGa - View Document |